TNFRSF17 and plasma cell myeloma: The existing preclinical studies and clinical trial results collectively suggest that GPRC5D‐targeted CAR‐T cells offer significant potential for patients with multiple myeloma, particularly those who relapse following anti‐BCMA treatment.